Akuffo, Emma L <br/><br/>
The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.  [electronic resource] 

 -  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals  Sep 2008 
 - 618-36 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1354-750X 
<br/><br/><label>Standard No.: </label>10.1080/13547500802445199  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Alzheimer Disease--drug therapy<br/>Apolipoproteins E--blood<br/>Biomarkers--blood<br/>Cognition--drug effects<br/>Complement C1 Inactivator Proteins--metabolism<br/>Complement C1 Inhibitor Protein<br/>Complement Factor H--metabolism<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Europe<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>New Zealand<br/>Nootropic Agents--therapeutic use<br/>Proteomics<br/>Reproducibility of Results<br/>Rosiglitazone<br/>Severity of Illness Index<br/>Thiazolidinediones--therapeutic use<br/>Time Factors<br/>Treatment Outcome<br/>alpha-Macroglobulins--metabolism